A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department

Prospective, single-site, open-label, non-controlled pilot study consisting of two parallel trials. Participants will receive rimegepant or zavegepant for acute migraine treatment during a single Emergency Department visit, with post-discharge follow-up through 28 days. Participants will be allocated to either the rimegepant trial or the zavegepant trial. The study design does not include a placebo or active comparator control group, and the two gepant study drugs are not designed to function as active comparator groups. The objective in this investigation is to examine relief from either rimegepant or zavegepant in separate parallel trials.

NCT Number	NCT07667621
Lead Sponsor	University of South Florida Collaborators: Pfizer, Tampa General Hospital
Conditions	Migraine, Migraine Disease, Migraine in Adults, Migraine Headache, Acute Migraine, Migraine Without Aura, Migraine With Aura
Enrollment	100 participants
Start Date	2026-07
Primary Completion	2027-07 (estimated)
Study Completion	2027-08 (estimated)
Updated on ClinicalTrials.gov	2026-06-25